Posted 23rd September 2019 by Joshua Sewell
Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.
Posted 18th September 2019 by Joshua Sewell
I can recall clearly the pathologists coming to lecture our medical school class our second year in 1993.
Most of them felt compelled to tell us, “Pathology is a lot of fun, you can make a good living, but don’t go into it, there aren’t any jobs.”
Posted 16th September 2019 by Liv Sewell
We spoke to John Griffin, CSO at Numerate, to find out how AI is changing drug discovery and development. Numerate is a drug design company applying cutting-edge AI to transform the process of small molecule drug design.
Posted 11th September 2019 by Joshua Sewell
Ahead of his presentation at the 6th Digital Pathology and AI Congress: Europe, we spoke to Andrew Janowczyk about his work creating scalable data analysis techniques to facilitate cancer research through the development of open-source Digital Pathology tools.
Posted 9th September 2019 by Joshua Sewell
As Chief Data Officer for the OSTHUS Group, Eric Little co-founded LeapAnalysis, a new approach to AI, data integration and analytics.
LeapAnalysis is the first fully federated and virtualised search and analytics engine that runs on semantic metadata. It allows users to combine semantic models (ontologies) with machine learning algorithms to provide customers with unparalleled flexibility in utilizing their data.
Posted 4th September 2019 by Liv Sewell
Most students and clinicians learn microbiology with the proper equipment: microscopes. However, in deprived countries front-line health facilities have to refer patients elsewhere because they do not have a microscope to enable diagnosis. Research is inhibited because of lack of equipment, students never get the opportunity to use real microscopes during their studies, and participation in science and particularly microbiology is very low.
Posted 30th August 2019 by Liv Sewell
NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.
Posted 28th August 2019 by Jane Williams
Following the 5th Digital Pathology & AI Congress: USA, we have made the following presentation slides available from Iman Hajirasouliha, Kim Solez and Mrinal Mandal.